TY  - CHAP
M1  - Book, Section
TI  - Assessing Drug Promotions
A1  - Ness, Genevieve Lynn
A1  - Beckett, Robert D.
A2  - Malone, Patrick M.
A2  - Witt, Benjamin A.
A2  - Malone, Meghan J.
A2  - Peterson, David M.
PY  - 2022
T2  - Drug Information: A Guide for Pharmacists, 7e
AB  - Learning  ObjectivesAfter  completing  this  chapter,  the  reader  will  be  able  to:Define  drug  promotions.List  recommendations  by  the  World  Health  Organization  (WHO)  for  appropriate  drug  promotions.Describe  the  role  of  the  U.S.  Food  and  Drug  Administration  (FDA)  Office  of  Prescription  Drug  Promotion  (OPDP).Determine  whether  a  piece  of  direct-to-consumer  advertising  (DTCA)  has  been  cited  in  FDA  warning  letters  to  companies.Describe  the  allowed  content  for  a  specific  type  of  DTCA.Evaluate  a  given  piece  of  DTCA  based  on  FDA  and  Pharmaceutical  Manufacturer’s  Association  (PhRMA)  guidelines.Report  a  drug  promotion  concern  using  the  Bad  Ad  Program.Evaluate  the  appropriateness  of  a  piece  of  drug  promotion  designed  for  a  health  care  professional.List  systematic  and  individual  strategies  that  may  be  used  to  combat  proliferation  of  misinformation  in  drug  promotions.Identify  logical  fallacies  used  in  drug  promotion,  when  given  an  interaction  with  a  pharmaceutical  industry  representative.Describe  the  goals  and  design  of  academic  detailing  programs.Describe  the  clinical,  economic,  and  humanistic  effects  of  academic  detailing.  
SN  - 
PB  - McGraw Hill
CY  - New York, NY
Y2  - 2024/04/19
UR  - accesspharmacy.mhmedical.com/content.aspx?aid=1190462315
ER  -